Drugs / REGRELOR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00099450 | Dec 2004 → Mar 2005 | cardiovascular disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00316212 | Apr → Aug 2006 | coronary artery disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGRELOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL1162175 ↗ |
| Known as | INS50589 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00316212 ↗ |
| Known as | REGRELOR DISODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1162175 ↗ |
| Action | Inhibit | “INS50589 is a well-tolerated, reversible, competitive antagonist of ADP at the P2Y(12) human platelet receptor” PMID 17654304 ↗ Aug 20071“Purinergic receptor P2Y12 antagonist” CHEMBL1162175 ↗ |
| Modality | Small molecule | — CHEMBL1162175 ↗ |
| Route | Intravenous | “Thirty-six subjects received intravenous infusions of placebo or INS50589 at 0.1-3 mg/kg/h for four hours.” PMID 17654304 ↗ Aug 2007 |
| Target | P2RY12 | “Purinergic receptor P2Y12 antagonist” CHEMBL1162175 ↗ |